Benzarone

Summary

Benzarone (CHEMBL1474963) is an approved small molecule.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• Chemistry: 266.29 Da · C17H14O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1474963
Name	Benzarone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	255968
Molecular formula	C17H14O3
Molecular weight	266.29
InChIKey	RFRXIWQYSOIBDI-UHFFFAOYSA-N

SMILES: CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC=C(C=C3)O

IUPAC name: (2-ethyl-1-benzofuran-3-yl)-(4-hydroxyphenyl)methanone

Also known as: Benzarona, Benzarone, L 2197, L-2197, NSC-82134, SID24424590, benzarone, BENZARONE, C0088585

Patent coverage: 123 distinct patent families (358 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 349 (97%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 3 (assay-derived). Sample: Protein phosphatase EYA3, Protein phosphatase EYA3, Solute carrier family 22 member 12.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 7 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
SLC22A12	5.55	IC50	2800	nM	CHEMBL_ACT_6172508

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).